Appointment of Non-Executive Director

RNS Number : 8149Y

Cambridge Cognition Holdings PLC

14 September 2020

 

Cambridge Cognition Holdings Plc

(' Cambridge Cognition ' or the 'Company ' )

Appointment of Non-Executive Director

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that Richard Bungay will join the Board as a Non-Executive Director with immediate effect.

Mr. Bungay has over 25 years' experience in corporate roles with R&D-based companies within the biotechnology and pharmaceutical sector, including as CFO of both public and private companies, with a particular focus on financing, investor relations and business development. Richard is currently CFO of Diurnal Group plc, the AIM quoted specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases.

Prior to that, Richard was CFO and Chief Operating Officer of Mereo BioPharma Group plc, a biopharmaceutical company focused on rare and specialty diseases. Richard's other experience includes being CFO of Glide Technologies, a device and development company focused on solid dose formulations of therapeutics and vaccines, and CFO of Verona Pharma plc, a drug development company focused on first-in-class medicines to treat respiratory diseases. 

Richard qualified as a Chartered Accountant with Deloitte in 1993.

The following information regarding the appointment of Richard Edward Bungay (aged 51) is required to be disclosed under Schedule 2(g) of the AIM Rules for Companies:

Current directorships and/or partnerships	Former directorships and/or partnerships (within the last five years)
Chroma Therapeutics Limited	Glide Pharmaceutical Technologies Limited
Diurnal Group plc	Mereo Biopharma Group plc
	The Forest School Academy Trust

There are no further disclosures to be made under Schedule 2(g) of the AIM Rules for Companies.

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014

Enquiries

Cambridge Cognition Holdings PLC
Matthew Stork, Chief Executive Officer Nick Walters, Chief Financial Officer	Tel: [phone] [e-mail]
finnCap Ltd (NOMAD and Joint Broker)	Tel: [phone]
Geoff Nash / Simon Hicks	(Corporate Finance)
Alice Lane / Manasa Patil	(Corporate Broking)
Dowgate Capital Limited (Joint Broker) David Poutney/ James Serjeant	Tel: [phone] (Corporate Broking)
IFC Advisory Limited (Financial PR and IR)	Tel: [phone]
Tim Metcalfe/ Graham Herring/ Zach Cohen

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

 

END

 

 

BOABIGDCDSBDGGB